ArticleTherapeutic advances in chronic disease2020

Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.

Ikaro Breder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.